Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 103.89

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	1/25/2012 9:42:21 PM
	Read Replies (1) of 3202

From the NVS quarterly report, INCY relevant (of course!), from novartis.com 1) Additional results from two pivotal Phase III trials for INC424 (ruxolitinib) showed promise for the treatment of myelofibrosis, a life-threatening blood cancer. The results from COMFORT-II showed a substantial improvement in patient-reported health-related quality of life and myelofibrosis symptoms for patients receiving INC424, but remained the same or worsened for patients receiving best available therapy. Additionally, in the COMFORT-I survival analysis, INC424 demonstrated an early overall survival advantage over placebo. 2) INC424 Myelofibrosis Q2 2011 - EMA decision expected in H1 2012 - Results from COMFORT-II showed a substantial improvement in patient-reported health-related quality of life and myelofibrosis symptoms compared with baseline for patients receiving INC424, but remained the same or worsened for patients receiving best available therapy - In post-hoc survival analysis in COMFORT-I, INC424 also demonstrated an early overall survival advantage over placebo 3) INC424 Polycythemia vera 2014 Ph III, no news update

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next